Skip to main
CATX

CATX Stock Forecast & Price Target

CATX Analyst Ratings

Based on 8 analyst ratings
Strong Buy
Strong Buy 63%
Buy 38%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Perspective Therapeutics is a radiopharmaceutical development company that has a promising technology utilizing alpha-emitting isotope Lead-212 for targeted cancer therapy. With a potential $39 billion addressable market and upcoming data catalysts for all three clinical programs in 2026, the company is well-positioned to become a frontrunner in the TAT space. However, risks to the attainment of the price target and rating include potential competition and difficulties with reimbursement and adoption of products.

Bears say

Perspective Therapeutics is a radiopharmaceutical company that has a potentially promising TAT treatment for cancer, as evidenced by pre-clinical data and support from key opinion leaders. However, the frontloading regimen and potential side effects may pose risks to adoption and reimbursement, which could negatively impact overall market potential and valuation for Perspective Therapeutics. It will be important to closely monitor clinical data and competition in the market for this company's success and potential stock performance.

CATX has been analyzed by 8 analysts, with a consensus rating of Strong Buy. 63% of analysts recommend a Strong Buy, 38% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Perspective Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Perspective Therapeutics Inc (CATX) Forecast

Analysts have given CATX a Strong Buy based on their latest research and market trends.

According to 8 analysts, CATX has a Strong Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.62, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.62, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Perspective Therapeutics Inc (CATX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.